Buprenorphine-Naloxone

Indications

• FDA-approved for the treatment of opioid dependence as part of a complete plan that includes counseling and psychosocial support.
• First-line maintenance treatment for opioid use disorder, halving all-cause and overdose mortality compared with no medication treatment.
• The X-waiver was eliminated by the Consolidated Appropriations Act of 2023, so any DEA-registered clinician can prescribe it in ordinary office practice.
• Suitable for outpatient induction and maintenance without the daily-dispensing structure that federal rules impose on methadone.
• Used off-label for chronic pain in patients with opioid use disorder, though buprenorphine monoproducts are the labeled analgesic options.
• Adolescent use is supported by AAP and ASAM guidance even where the specific product label does not carry a pediatric indication.

Mechanism of action

• Buprenorphine is a partial mu-opioid agonist with a ceiling on respiratory depression, giving a wide safety margin relative to full agonists.
• Extremely high mu receptor affinity displaces full agonists, which relieves craving and blocks the effect of heroin, fentanyl and oxycodone.
• That same high affinity precipitates withdrawal if given while a full agonist still occupies receptors, which is why induction timing matters.
• Kappa receptor antagonism may contribute to improved mood and reduced dysphoria during early recovery on maintenance therapy.
• Naloxone has under 10% sublingual bioavailability and is present only to deter injection, where it would precipitate withdrawal.

Pharmacokinetics

• Sublingual bioavailability of buprenorphine is roughly 30%; swallowed drug is destroyed by first-pass metabolism and is clinically inert.
• Elimination half-life is 24-42 h, which supports once-daily and even alternate-day dosing once a patient is stable on maintenance.
• Metabolized by CYP3A4 to the weakly active norbuprenorphine, then glucuronidated by UGT1A1 and UGT2B7 before mainly fecal excretion.
• CYP3A4 inhibitors such as ritonavir, ketoconazole and clarithromycin raise concentrations, while rifampin, carbamazepine and phenytoin can drop them into withdrawal.
• No renal dose adjustment is needed, but severe hepatic impairment raises exposure to both components and favors a buprenorphine monoproduct.

Dosing

• Induce only when objective withdrawal is present, generally a COWS score of 8-12 or higher and 12-24 h after the last short-acting opioid.
• Day 1: give up to 8 mg/2 mg in divided doses starting with 2 mg/0.5 mg to 4 mg/1 mg; Day 2 may be given as a single 16 mg/4 mg dose.
• Maintenance is usually 16 mg/4 mg daily with a labeled range of 4 mg/1 mg to 24 mg/6 mg; doses under 8 mg predict dropout and return to use.
• Low-dose or micro-dose cross-induction lets patients on fentanyl or methadone start without waiting for full withdrawal, an off-label but widely used approach.
• The film or tablet must dissolve fully under the tongue or against the cheek; it cannot be cut, chewed or swallowed, and no food or drink until dissolved.
• Taper gradually if stopping, but counsel that discontinuation sharply raises overdose risk and that indefinite maintenance is an acceptable outcome.

Adverse effects

• Constipation, headache, nausea, sweating, insomnia and oral mucosal irritation are the common complaints, each in roughly 10-15% of patients.
• Dental caries, tooth loss and dental infections prompted an FDA safety communication in 2022; advise rinsing with water and delaying brushing.
• Precipitated withdrawal from premature induction is severe, prolonged and the main reason patients refuse to try buprenorphine again.
• Respiratory depression is uncommon alone but real when combined with benzodiazepines, alcohol, gabapentinoids or other sedatives.
• Transaminase elevation and rare hepatitis occur, particularly with hepatitis C coinfection or intravenous misuse of the formulation.
• Neonatal opioid withdrawal syndrome follows in utero exposure but tends to be milder and shorter than with methadone.

Monitoring

• Score withdrawal with COWS before the first dose and during induction, and document objective signs rather than patient report alone.
• Baseline liver function tests with periodic repeat, plus hepatitis B and C and HIV screening in anyone with injection drug use.
• Urine drug testing that distinguishes buprenorphine from norbuprenorphine helps confirm actual dosing rather than film tampering.
• Check the prescription drug monitoring program at initiation and periodically, and document counseling and psychosocial engagement.
• Ask about oral health at least yearly and refer for dental care given the caries signal with sublingual formulations.

Interactions

• Benzodiazepines and other CNS depressants raise respiratory depression risk, but the FDA specifically warns against withholding buprenorphine for that reason alone.
• CYP3A4 inhibitors including ritonavir, azole antifungals and macrolides increase exposure and may require a dose reduction.
• CYP3A4 inducers such as rifampin, carbamazepine, phenytoin and efavirenz can lower levels enough to cause withdrawal and craving.
• Naltrexone and other opioid antagonists are contraindicated, and full opioid agonists given for pain will be substantially blocked.
• Modest QT effects are far less than with methadone, but combine cautiously with other QT-prolonging drugs in patients with cardiac risk.

Special populations

• Pregnancy: buprenorphine is a preferred medication for opioid use disorder; the combination product is increasingly considered acceptable, with monoproduct an alternative.
• Lactation: milk levels are low and breastfeeding is encouraged if the patient is stable and not using illicit drugs, with infant sedation monitoring.
• Pediatric labeling generally starts at age 16, but AAP and ASAM support treating younger adolescents with opioid use disorder off-label.
• Geriatric patients tolerate maintenance well; watch for sedation, constipation, falls and interactions with other CNS depressants.
• Hepatic: no change in mild disease, halve doses or avoid the combination product in moderate to severe impairment, and no renal adjustment is required.

Clinical pearls

• Wait for objective withdrawal, COWS 8-12 or higher, or you will precipitate a miserable withdrawal.
• No X-waiver since 2023: any DEA registrant can prescribe it in routine office practice.
• Aim for 16 mg/day; under-dosing below 8 mg is the commonest cause of treatment dropout.